Regulatory B cells in myasthenia gravis are differentially affected by therapies

We analyzed the number and functionality of regulatory B (Breg) cells in well‐defined myasthenia gravis patients. We first showed a decreased number of circulating CD19+CD24++CD38++ Breg cells and an altered functionality of Breg cells in untreated myasthenia gravis patients. Next, we demonstrated that the proportion of circulating Breg cells was restored in myasthenia gravis patients after thymectomy, probably as Breg cells could be sequestered in the myasthenia gravis thymus. In contrast, corticosteroid treatments did not restore and decreased even more the proportion of Breg cells in myasthenia gravis patients. These results clearly demonstrated that two distinct immunomodulatory therapies affect differentially Breg cells.

[1]  Zhuogang Liu,et al.  The Role of Regulatory B Cells in Patients with Acute Myeloid Leukemia , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[2]  Qiang Sun,et al.  Regulatory B Cells in Seropositive Myasthenia Gravis versus Healthy Controls , 2017, Front. Neurol..

[3]  L. Hobson‐Webb,et al.  B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity , 2017, Front. Neurol..

[4]  B. Soliven,et al.  Impaired regulatory B cells in myasthenia gravis , 2016, Journal of Neuroimmunology.

[5]  A. Marx,et al.  Randomized trial of thymectomy in myasthenia gravis. , 2016, Journal of thoracic disease.

[6]  R. Sobel,et al.  CNS accumulation of regulatory B cells is VLA-4-dependent , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[7]  T. Cai,et al.  The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy , 2015, Journal of Neuroimmunology.

[8]  E. Rosser,et al.  Regulatory B cells: origin, phenotype, and function. , 2015, Immunity.

[9]  J. Howard,et al.  Characterization of B cells in muscle-specific kinase antibody myasthenia gravis , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[10]  B. Soliven,et al.  CD1dhiCD5+ B Cells Expanded by GM-CSF In Vivo Suppress Experimental Autoimmune Myasthenia Gravis , 2014, The Journal of Immunology.

[11]  M. Hahne,et al.  Regulatory B10 Cells Are Decreased in Patients With Rheumatoid Arthritis and Are Inversely Correlated With Disease Activity , 2014, Arthritis & rheumatology.

[12]  S. Berrih-Aknin,et al.  Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. , 2014, Journal of autoimmunity.

[13]  Li Yang,et al.  Interleukin‐10 producing‐B cells and their association with responsiveness to rituximab in myasthenia gravis , 2014, Muscle & nerve.

[14]  D. Isenberg,et al.  CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation , 2013, Science Translational Medicine.

[15]  J. D. de Winter.  Using the Student ’ s t-test with extremely small sample sizes , 2013 .

[16]  P. Menheere,et al.  Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission , 2011, Journal of Neuroimmunology.

[17]  R. Mantegazza,et al.  Current and emerging therapies for the treatment of myasthenia gravis , 2011, Neuropsychiatric disease and treatment.

[18]  D. Isenberg,et al.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. , 2010, Immunity.

[19]  M. Fujimoto,et al.  Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. , 2008, The Journal of clinical investigation.

[20]  D. Gray,et al.  Not always the bad guys: B cells as regulators of autoimmune pathology , 2008, Nature Reviews Immunology.

[21]  D. Gray,et al.  Prevention of Arthritis by Interleukin 10–producing B Cells , 2003, The Journal of experimental medicine.